MedTrace Logo

A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty

NCT04298528 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2023-01-10

No results posted yet for this study

Summary

The primary purpose of this study was to determine if cannabinoid use decreases narcotic consumption in patients undergoing total knee arthroplasty (TKA).

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Dronabinol

2.5mg 2 times a day for 30 days after total knee replacement

OTHER

Placebo

2 times a day for 30 days after total knee replacement

Sponsors & Collaborators

  • Colorado Joint Replacement

    lead OTHER

Principal Investigators

  • Jason M Jennings, MD DPT · Colorado Joint Replacement

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-05
Primary Completion
2024-02-05
Completion
2025-02-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298528 on ClinicalTrials.gov